[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591694":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":10,"responsibleParty":34,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":10},{"fullName":5,"class":6},"Fayoum University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1",null,"participants with metabolic syndrome",[13],"Drug: Erythropoietin",{"label":15,"type":10,"description":16,"interventionNames":17},"group 2","participants without metabolic syndrome",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Erythropoietin","EPO resistance",[9,15],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Nada Elsayed, Bachelor","CONTACT","01000766880","ne1189@fayoum.edu.eg",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Dr. Marwa Tolba, Assistant Professor","01067789982","Mka05@fayoum.edu.eg",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Nada Elsayed Abdeltwab Issa","Teaching Assistant","100591694","evaluation-of-erythropoietin-therapy-in-patients-with-end-stage-kidney-disease-on-regular-hemodialysis-hemoglobin-outcomes-and-metabolic-syndrome-as-a-risk-factor-for-erythropoietin-resistance--100591694",false,"NCT06983756","\" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance \"","Inclusion Criteria:\n\n* Patients (and replacements) will be randomly selected by a raffle.\n* All participants should be 18 years of age or older and agree to participate in the study after due clarification.\n* Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.\n\nExclusion Criteria:\n\n* \\- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.\n* Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.\n* Patients with infection or autoimmune diseases.","ALL","18 Years",{"count":47,"type":48},66,"ESTIMATED","OBSERVATIONAL","The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).",[52],"Erythropoietin Resistant Anemia (EPO Resistant Anemia)","NOT_YET_RECRUITING","2025-05-14",{"date":56,"type":57},"2025-05-21","ACTUAL",{"date":59,"type":48},"2025-06-01",{"date":61,"type":48},"2026-01-01",{"name":5,"class":6}]